Interpretation of 2024 EACTS guidelines on perioperative medication in adult cardiac surgery
- VernacularTitle:《2024 EACTS成人心脏手术围手术期药物治疗管理指南》解读
- Author:
Yunpeng ZHU
1
;
Heng ZHANG
2
,
3
;
Mengyuan HAN
1
;
Jiawei HAN
2
,
3
;
Zhe ZHENG
2
,
3
;
Qiang ZHAO
1
Author Information
1. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China
2. National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China
3. National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, P. R. China
- Publication Type:Journal Article
- Keywords:
Cardiac surgery;
perioperative medication;
secondary prevention;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(09):1216-1224
- CountryChina
- Language:Chinese
-
Abstract:
The European Association for Cardio-Thoracic Surgery (EACTS) has recently updated and published the "2024 EACTS guidelines on perioperative medication in adult cardiac surgery". Based on the latest evidence, the guidelines have been updated in multiple aspects including underlying disease management, antithrombotic medication, arrhythmia treatment and other supportive care, etc. This paper aims to summarize and interpret the guidelines, in order to promote clinicians’ understanding and optimize perioperative medical treatment in adult cardiac surgery.
